Venus Remedies Intrinsic Value
Venus Remedies intrinsic value. Venus Remedies (VENUSREM) median intrinsic value is ₹1630.00 from 10 valuation models (range ₹539–₹3127), vs current price ₹1796.10 — -9.2% downside (Trading Near Calculated Value), margin of safety -10.2%. For current market price and key ratios, visit Venus Remedies share price screener.
VENUSREM Valuation Methods Summary — DCF, Graham Number & P/E
Venus Remedies intrinsic value across 10 models vs current price ₹1796.10 — upside/downside and value range per method. Compare with VENUSREM stock valuation models to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3126.64 | ₹2501.31 - ₹3751.97 | +74.1% | EPS: ₹142.12, Sector P/E: 22x |
| Book Value Method | asset | ₹1021.54 | ₹919.39 - ₹1123.69 | -43.1% | Book Value/Share: ₹510.77, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1624.62 | ₹1462.16 - ₹1787.08 | -9.5% | Revenue/Share: ₹812.31, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2092.31 | ₹1883.08 - ₹2301.54 | +16.5% | EBITDA: ₹272.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1630.00 | ₹1304.00 - ₹1956.00 | -9.2% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹909.57 | ₹818.61 - ₹1000.53 | -49.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹2195.75 | ₹1976.17 - ₹2415.33 | +22.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2363.08 | ₹2126.77 - ₹2599.39 | +31.6% | ROE: 28.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1021.54 | ₹919.39 - ₹1123.69 | -43.1% | EPS: ₹142.12, BVPS: ₹510.77 |
| Dividend Yield Method | dividend | ₹538.83 | ₹484.95 - ₹592.71 | -70.0% | DPS: ₹10.00, Target Yield: 2.5% |
VENUSREM Intrinsic Value vs Market Price — All Valuation Models
Venus Remedies fair value range ₹539–₹3127 vs current market price ₹1796.10 across 10 valuation models. Read VENUSREM dividend track record for the complete payout history and dividend yield track record.
VENUSREM Intrinsic Value Analysis — Undervalued or Overvalued?
Venus Remedies median intrinsic value ₹1630.00, current price ₹1796.10 — Trading Near Calculated Value by 9.2%, margin of safety -10.2%.
What is the intrinsic value of VENUSREM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Venus Remedies (VENUSREM) is ₹1630.00 (median value). With the current market price of ₹1796.10, this represents a -9.2% variance from our estimated fair value.
The valuation range spans from ₹538.83 to ₹3126.64, indicating ₹538.83 - ₹3126.64.
Is VENUSREM undervalued or overvalued?
Based on our multi-method analysis, Venus Remedies (VENUSREM) appears to be trading near calculated value by approximately 9.2%.
VENUSREM Financial Health — Key Ratios vs Industry Benchmarks
Venus Remedies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.11 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 28.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.24x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VENUSREM Cash Flow Quality — Operating & Free Cash Flow
Venus Remedies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹156 Cr | ₹64 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹86 Cr | ₹48 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹37 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹37 Cr | ₹8 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹41 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |